Yep without the Ferring payment, the number would have been about $26M. It was a very good quarter and conference call, and it looks like Antares has finally turned the corner. They are nearly cash-flow positive, and are.almost covering their sales expense for Xyosted in the first six months!
My model only took a couple hours and is very crude. Some cells only have numbers and no formulas right now until I do some more work. For the first time, Antares is starting to break out individual product sales like Otrexup and Xyosted which is helpful. For Antares’ model, it’s all about the sales. And by the way, the numbers Simon’s getting for his spreadsheet are very accurate, which is good to know. Unfortunately, Antares’ partnered products are a little more difficult to track and forecast without knowing the exact percentages. Hope Teva can get its act together, and I will be interested to hear what they have to say on their call.
News 
Market Data 
Discover 
